MedTrace Logo

Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma

NCT03042247 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-06-12

No results posted yet for this study

Summary

According to the most recent guidelines, total-body imaging techniques are an indispensable element in the staging and post-treatment re-evaluation in patients with lymphoma. Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is the gold-standard for the assessment of the disease in these patients. The use of alternative methods, without radiation, such as whole-body magnetic resonance imaging (MRI), could be a valid alternative; this would result an advantage, considering the young age of the majority of patients at diagnosis and the need to undergo to serial assessments. The recent introduction of combined PET total body MRI (PET/MRI) offers the possibility to integrate morphological information with the high resolution of MRI with the metabolic activity of PET, through the uptake of FDG, for a more accurate definition of the extent of disease in patients with lymphoma.

Conditions

  • Diffuse Large B-cell-lymphoma
  • Classical Hodgkin Lymphoma

Interventions

DIAGNOSTIC_TEST

FDG PET/TC and FDG PET/MRI

Combined assessment with FDG PET/TC and PET/MRI

Sponsors & Collaborators

  • Federico II University

    collaborator OTHER

  • Marco Picardi

    lead OTHER

Principal Investigators

  • Fabrizio Pane, Prof · Hematology - AOU Federico II - Naples - Italy

  • Marco Picardi, Prof · Hematology - AOU Federico II - Naples - Italy

  • Andrea Soricelli, Prof · IRCSS SDN - Naples - Italy

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-24
Primary Completion
2020-06-10
Completion
2021-02-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03042247 on ClinicalTrials.gov